Vanessa Young of Oakville, Ontario died suddenly on March 19, 2000 at age 15. She was taking cisapride, a drug prescribed to “enhance stomach emptying” of whose link to fatal cardiac dysrhythmias the US FDA warned American doctors two months earlier.Health Canada delayed its own alert until after Vanessa’s sudden cardiac arrest at home.1 Her father Terence Young became the Conservative MP for … [Read more...]
Do proton pump inhibitors increase mortality? A systematic review and in‐depth analysis of the evidence
Pharmacol Res Perspect. 2020; 8:e651. Ben‐Eltriki, M, Green, CJ, Maclure, M, Musini, V, Bassett, KL, Wright, JM Abstract: Proton pump inhibitors (PPIs) were primarily approved for short‐term use (2 to 8 weeks). However, PPI use continues to expand. Widely believed to be safe, we reviewed emerging evidence on increased mortality with PPI long‐term use. Our 2016 systematic PPI drug class … [Read more...]
Effectiveness and Safety among Direct Oral Anticoagulants in Non Valvular Atrial Fibrillation: A Multi‐Database Cohort Study with Meta‐Analysis
British Journal of Clinical Pharmacology, November 2020 Madeleine Durand, Mireille E. Schnitzer, Menglan Pang, Greg Carney, Sherif Eltonsy, Kristian B. Filion, Anat Fisher, Min Jun, I. fan Kuo, Alexis Matteau, J. Michael Paterson, Jacqueline Quail, Christel Renoux for the Canadian Network for Observational Drug Effect Studies (CNODES) Investigators Abstract Background: There are conflicting … [Read more...]
[126] Serious harms with long-term PPI use in older adults
Proton pump inhibitors (PPIs) were introduced in 1988. Health Canada, professional, and academic groups all agree that they should be prescribed at the lowest dose and for the shortest duration appropriate to the condition treated. However, PPI use continues to expand. Between 2000 and 2018 BC’s population grew by 20%, but use of PPIs increased by 257%. In 2018, 442,559 British Columbians (9% of … [Read more...]
Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study
BMJ 2020; 370 DOI: https://doi.org/10.1136/bmj.m3342 (Published 23 September 2020) Kristian B Filion, Lisa M Lix, Oriana HY Yu, Sophie Dell’Aniello, Antonios Douros, Baiju R Shah, Audray St-Jean, Anat Fisher, Eric Tremblay, Shawn C Bugden, Silvia Alessi-Severini, Paul E Ronksley, Nianping Hu, Colin R Dormuth, Pierre Ernst, Samy Suissa, on behalf of the Canadian Network for Observational Drug … [Read more...]
[Jun 10] Shedding light on risks with anticholinergic drug use – Practical tips for patient care
TI Best Evidence Webinar Shedding light on risks with anticholinergic drug use – Practical tips for patient care This event has already taken place. Scroll down to view a video recording of the webinar. PRESENTER: Dr. Aaron M Tejani, PharmD. DATE: Wednesday, June 10, 2020 CME CREDITS: MainPro+/MOC Section 1 credits: 1.0. You must register, attend the webinar and complete the … [Read more...]
Communicating emerging risks of SGLT2 inhibitors—timeliness and transparency of medicine regulators
BMJ 2020; 369:m1107 (Published 29 April 2020) DOI: https://doi.org/10.1136/bmj.m1107 Key messages Sodium glucose co-transporter-2 (SGLT2) inhibitors came to market amid heightened concern over the safety of diabetes drugs The drugs have received several serious safety warnings since approval, but the number, timeliness, and strength of these safety communications have differed … [Read more...]
